Esophageal cancer marker and use thereof

Abstract

The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.

1 . A method for prevention or treatment of Glypican-1-positive malignant tumor in a subject, comprising administering an effective amount of a Glypican-1 suppressant to the subject in need thereof. 
     
     
         2 . The method of  claim 1 , wherein the Glypican-1-positive malignant tumor is the esophageal cancer. 
     
     
         3 . The method of  claim 2 , wherein the esophageal cancer comprises those in lymph node metastasis sites, squamous cell carcinoma, and/or adenocarcinoma. 
     
     
         4 . The method of  claim 2 , wherein the esophageal cancer comprises squamous cell carcinoma. 
     
     
         5 . The method of  claim 1 , wherein the Glypican-1 suppressant is an antibody or nucleic acid. 
     
     
         6 . The method of  claim 1 , wherein the Glypican-1 suppressant is an antibody and the antibody binds to positions 33 to 61 of SEQ ID NO: 2; positions 339 to 358 and/or positions 388 to 421 of SEQ ID NO: 2; or positions 430 to 530 of SEQ ID NO: 2, as an epitope. 
     
     
         7 . The method of  claim 6 , wherein the antibody is an antibody selected from monoclonal antibody, polyclonal antibody, chimeric antibody, humanized antibody, human antibody, multifunctional antibody, bispecific or oligospecific antibody, single chain antibody, scFV, diabody, sc(Fv) 2  (single chain (Fv) 2 ), and scFv-Fc. 
     
     
         8 . The method of  claim 1 , wherein the Glypican-1 suppressant is nucleic acid and the nucleic acid is siRNA. 
     
     
         9 . The method of  claim 8 , wherein the siRNA comprises SEQ ID NO: 25 and/or SEQ ID NO: 26.